Dr. Constantinides is President of Biopharmaceutical & Drug Delivery Consulting, LLC in Gurnee, Illinois, USA that he founded in 2004, and he has more than 30 years of industrial experience in drug delivery and pharmaceutical development. He received a University Diploma in Chemistry from Athens University in 1977 and PhD in Biochemistry from Brown University in 1983. He was a postdoctoral fellow in the Pharmacology Department and Associate Research Scientist in the Comprehensive Cancer Center of Yale University School of Medicine (1983-1987). Past industrial positions held included: Vice President of R&D with DOR Biopharma and Morton Grove Pharmaceuticals (2000-2004), Director of Research at SONUS Pharmaceuticals (1997-2000) and from 1987 to 1997 a number of R&D positions of increasing responsibilities with LipoGen, SmithKline Beecham Pharmaceuticals and Abbott Laboratories.. He has heald adjunct faculty appointmnets with Roosevelt University College of Pharmacy in Schaumburg, Illinois, the Pharmaceutics Department of Washington University in Seattle, Washington and the Department of Biochemistry of the University of Tennessee, in Knoxville, Tennessee. He is inventor in 33 patents and patent applications, has authored more than 130 publications including review articles, book chapters and presentations on the parenteral and oral drug delivery of small molecules and peptides/proteins and has presented more than 100 invited talks at many national and international conferences, pharmaceutical companies and universities. Dr. Constantinides is AAPS Fellow, Past Chair of the AAPS Formulation Design and Development (FDD) Section, the Nanotechnology and Lipid-Based Drug Delivery Systems Focus Groups. He has received numerous honors and awards and serves as Associate Editor of the AAPS Open journal since its launch in the fall of 2015.
Drug formulation and delivery, pharmaceutical nanotechnology, lipid-based drug delivery systems, developing and applying enabling drug delivery technologies to improve poor drug solubility and/or permeability in drug discovery and product line extensions, oral peptide/protein delivery.
Arwyn obtained a Ph.D. in protein-crystallography at Birkbeck College, University of London and undertook postdoctoral endocytosis research at the University of Liverpool, Harvard University, and EMBL-Heidelberg as EMBO and Alexander von Humboldt fellow. Appointed as a lecturer at the Cardiff University School of Pharmacy and Pharmaceutical Sciences in 2001 he is now Professor of Membrane Traffic and Drug Delivery. His research falls within cancer cell biology, endocytosis, and drug delivery. A major objective understands endocytosis to improve the cellular delivery efficiency of drug delivery vectors including peptides, natural and synthetic nanoparticles and antibodies targeting plasma membrane receptors. Recent work has concentrated on strategic approaches to plasma membrane targeting to stimulate endocytosis and intracellular targeting. Arwyn has published widely within these fields and his group has made significant contributions to the current understanding of the way drug delivery vectors interact with cells and enter endocytic pathways that govern their intracellular fate.
Cancer cell biology, endocytosis, and drug delivery